Welcome to our dedicated page for Precision Optics SEC filings (Ticker: POCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Precision Optics Corporation, Inc. (NASDAQ: POCI), a vertically integrated optics company serving healthcare and defense/aerospace markets. Although specific filings are not listed here, POCI’s reports on EDGAR typically include annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, along with other required disclosures.
Through these filings, Precision Optics presents detailed information about its business, which centers on proprietary micro-optics, 3D imaging and digital imaging technologies. The company describes how it supports medical device and defense/aerospace customers from new product concept through mass manufacture, including engineering and production revenue streams, facility expansions and risk factors related to demand, supply chains and economic conditions.
Stock Titan’s platform enhances these documents with AI-powered summaries that explain key sections of lengthy filings in plain language. For example, users can quickly see how management discusses trends in engineering versus production revenue, how non-GAAP measures such as Adjusted EBITDA are reconciled to GAAP results, and how the company characterizes its exposure to healthcare and defense/aerospace markets.
Investors can use this page to monitor new 10-K and 10-Q filings as they are posted to EDGAR in real time, as well as any 8-K current reports that may describe material events such as new development agreements, facility moves or changes in capital structure. Where applicable, insider transaction reports on Form 4 and proxy statements on Schedule 14A can also be reviewed to understand equity compensation practices and ownership changes.
By combining official SEC documents for POCI with AI-generated insights, this page helps users navigate complex regulatory filings and focus on the disclosures most relevant to Precision Optics’ optical instrument business.
COLL WAYNE M reported acquisition or exercise transactions in this Form 4 filing.
PRECISION OPTICS CORPORATION, INC. Chief Financial Officer Wayne M. Coll received a grant of 1,568 shares of common stock on March 31, 2026 as compensation. The shares were issued under an Employment Agreement that allows up to $25,000 per year of salary to be paid in stock.
The stock was priced at a quarterly volume weighted average price of $3.985 for the quarter ended March 31, 2026, based on payroll withholdings. After this grant, Coll directly owns 36,807 shares of Precision Optics common stock.
PRECISION OPTICS CORPORATION, INC. Chief Financial Officer Wayne M. Coll reported an open-market purchase of the company’s Common Stock. On March 30, 2026, he bought 20,833 shares at a price of $3.60 per share in an underwritten public offering. Following this transaction, he directly owns 35,239 shares of Precision Optics common stock.
Precision Optics Corporation, Inc. CEO Joseph Norman Forkey bought 1,388 shares of common stock in an open-market purchase. The transaction was completed at $3.60 per share in connection with an underwritten public offering. Following this purchase, he directly holds 143,959 common shares.
PRECISION OPTICS CORPORATION, INC. Chief Operating Officer Joseph Traut bought 41,666 shares of Common Stock at $3.60 per share in an underwritten public offering. This open-market purchase increased his directly held stake to 41,666 shares.
The transaction was reported as a standard open-market purchase, with each share acquired at the public offering price set for the underwritten deal.
Precision Optics Corporation, Inc. shareholders Norman, Sandra, and Brian Pessin report their updated ownership on an amended Schedule 13D. Norman H. Pessin holds 429,247 common shares, or 3.9% of the company. Sandra F. Pessin holds 477,361 shares, or 4.4%, and Brian L. Pessin holds 550,673 shares, or 5.0%.
Their shares were acquired with personal funds for a total purchase cost of about $1.65 million for Norman, $1.40 million for Sandra, and $1.87 million for Brian, including commissions. They originally bought the stock believing it was undervalued and state they may buy more, sell shares, communicate with management and the board, propose changes to capitalization or operations, or use hedging and short-selling strategies depending on market conditions and the company’s situation. Recent transactions in the past sixty days were effected through a prospectus supplement offering dated March 30, 2026.
Precision Optics Corporation, Inc. entered into an underwriting agreement with Lucid Capital Markets for an underwritten public offering of 2,777,777 shares of common stock at $3.60 per share. The company also granted a 45-day over-allotment option for up to 416,667 additional shares at the same public offering price, less the underwriting discount.
The company expects net proceeds of approximately $10.7 million, assuming full exercise of the over-allotment option, after underwriting discounts, commissions and expenses. It plans to use the proceeds for working capital and general corporate purposes. The offering, made off an effective Form S-3 shelf registration, closed on March 30, 2026.
In connection with the deal, the underwriter received a discount of up to 6.5% of gross proceeds, reimbursement of certain expenses up to $90,000, and Representative’s Warrants to purchase up to 159,722 shares at an exercise price of $4.21 per share, exercisable from March 30, 2026 until March 27, 2031.
Precision Optics Corporation, Inc. is conducting a primary offering of 2,777,777 shares of common stock at a public offering price of $3.60 per share via a prospectus supplement dated March 27, 2026. The company expects net proceeds of approximately $9.3 million to be used for working capital and general corporate purposes.
The offering permits the underwriters to purchase an additional 416,667 shares within 45 days. The prospectus lists 7,733,857 shares outstanding as of March 23, 2026 and shows expected common shares outstanding after the offering of 10,511,634 (or 10,928,301 if the option is exercised).
Precision Optics Corporation, Inc. is offering shares of common stock and, at investors' election, pre-funded warrants exercisable for one share at an exercise price of $0.01 per share. The company states its common stock trades on Nasdaq under the symbol POCI and cites a public float market value of $36.3 million computed as of March 25, 2026 based on 7,733,857 shares outstanding as of such date, of which 6,110,561 were held by non-affiliates.
The prospectus supplement describes customary underwriter terms, including a 45-day option to purchase additional shares, lock-up arrangements, and a representative’s warrant equal to 5.0% of shares sold. Net proceeds are expected to be used for working capital and general corporate purposes. The offering disclosure highlights immediate dilution risk, exercise limitations for pre-funded warrants tied to 4.99% or 9.99% beneficial ownership caps, and that the pre-funded warrants will not be listed on any exchange.
Precision Optics Corporation, Inc. held its annual stockholder meeting on March 19, 2026, with 5,950,539 shares voting, representing about 77.07% of the 7,720,229 shares outstanding as of January 29, 2026. Stockholders elected all five director nominees: Peter H. Woodward, Andrew J. Miclot, Buell G. Duncan, Joseph P. Pellegrino, Jr., and Joseph N. Forkey.
Investors also approved, on an advisory basis, the executive compensation program, with 3,009,650 votes for, 4,802 against, and 59,636 abstentions, alongside 2,876,451 broker non-votes. In addition, stockholders ratified the appointment of Stowe & Degon, LLC as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 5,949,026 votes for, 415 against, and 1,098 abstentions.
Precision Optics Corporation director Andrew J. Miclot exercised stock options for 20,000 shares of Common Stock at an exercise price of $1.44 per share on March 12, 2026. To cover tax obligations, 6,372 shares were withheld at $4.52 per share, leaving him with 13,628 shares of Common Stock held directly after the transactions.